Patient-specific induced pluripotent stem cells (iPSCs) represent a novel system for modeling human genetic disease and could provide a source of cells for large-scale drugdiscovery screens. Here we demonstrate the feasibility of performing a primary screen in neural crest precursors derived from iPSCs that were generated from individuals with familial dysautonomia (FD), a rare, fatal genetic disorder affecting neural crest lineages. We tested 6,912 small-molecule compounds and characterized eight that rescued expression of IKBKAP, the gene responsible for FD. One of the hits, SKF-86466, was found to induce IKBKAP transcription through modulation of intracellular cAMP levels and PKA-dependent CREB phosphorylation. SKF-86466 also rescued IKAP protein expression and the disease-specific loss of autonomic neuronal marker expression. Our data implicate alpha-2 adrenergic receptor activity in regulating IKBKAP expression and demonstrate that small-molecule discovery using an iPSC-based disease model can identify candidate drugs for potential therapeutic intervention.
l e t t e r s
Patient-specific induced pluripotent stem cells (iPSCs) represent a novel system for modeling human genetic disease and could provide a source of cells for large-scale drugdiscovery screens. Here we demonstrate the feasibility of performing a primary screen in neural crest precursors derived from iPSCs that were generated from individuals with familial dysautonomia (FD), a rare, fatal genetic disorder affecting neural crest lineages. We tested 6,912 small-molecule compounds and characterized eight that rescued expression of IKBKAP, the gene responsible for FD. One of the hits, SKF-86466, was found to induce IKBKAP transcription through modulation of intracellular cAMP levels and PKA-dependent CREB phosphorylation. SKF-86466 also rescued IKAP protein expression and the disease-specific loss of autonomic neuronal marker expression. Our data implicate alpha-2 adrenergic receptor activity in regulating IKBKAP expression and demonstrate that small-molecule discovery using an iPSC-based disease model can identify candidate drugs for potential therapeutic intervention.
Familial dysautonomia (FD) is an autosomal recessive disease caused by a single point mutation in the I-κ-B kinase complex-associated protein (IKBKAP) gene, leading to IKBKAP mis-splicing and a marked reduction in IKAP protein 1 . We previously reported the isolation of iPSC lines from FD fibroblasts and identified multiple diseasespecific phenotypes 2 . These phenotypes include low levels of wildtype (WT) IKBKAP expression, particularly in FD-iPSC-derived neural crest (FD-NC), which may partly explain why the disease specifically affects the peripheral nervous system. FD is a progressive neurodegenerative disorder without effective treatment. The identification of compounds that increase IKBKAP expression in affected cell types could yield novel therapies for FD.
Several recent disease modeling studies have demonstrated the use of iPSC-derived cell types for validating small sets of drug candidates [2] [3] [4] [5] [6] [7] [8] [9] . However, to move from validating a few compounds to screening larger chemical libraries, it is critical to define diseaserelevant conditions suitable for use in high-throughput screening (HTS) (Fig. 1a) . The first step in this process is large-scale production of the pertinent cell type. We have previously reported the prospective isolation of FD-NC precursors by flow cytometry 2 (Fig. 1b) .
Here we grew purified FD-NC precursors in the presence of FGF2 and EGF for 2 weeks (Fig. 1c) and cryo-preserved large batches (10 8 -10 9 cells) for subsequent screening applications. NC precursors showed stable growth properties (population doubling time: 44.2 h; Ki-67 + cells: 51.7 ± 2.4%), high purity, maintenance of neurogenic differentiation potential and excellent post-thawing recovery rates (91.6 ± 5.7%; Fig. 1c and Supplementary Fig. 1) . Optimized cell-plating conditions for 384-well microtiter plates were obtained using a laminin/fibronectin-based coating method ('in house' coating; Online Methods and Supplementary Fig. 2a ) that achieved reproducible cell attachment with high viability (Fig. 1d) . Cellular growth was monitored using Alamar Blue 10 and Hoechst nuclear staining 11 , which defined suitable plating densities at 2,500-7,500 cells/well ( Fig. 1d and Supplementary Fig. 2b,c) . DMSO had no major impact on growth of FD-NC precursors up to 1% DMSO (v/v). The final step in developing an FD-NC based HTS assay was the selection of a sensitive and disease-relevant readout. We hypothesized that promising compounds should increase levels of WT-IKBKAP in patient-specific cells and thereby increase the levels of IKAP protein. Therefore, we developed a qRT-PCR assay for measuring levels of WT-IKBKAP against the 18S internal control based on published primer sets 12 (Supplementary Fig. 2d ). Levels of mutant (MU)-IKBKAP were also determined to address whether compounds increase both WT and MU-IKBKAP or act by means of IKBKAP splicing 12 . Transcript levels were measured after cell lysis, RNA extraction, qRT-PCR reaction and data quantification ( Supplementary Table 1 ). RT-PCR technology is not commonly used in HTS and is highly dependent on the quality and quantity of the isolated RNA. We found that a plating large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression l e t t e r s density of 7,500 cells/well yielded excellent reproducibility. To further validate our RT-PCR assay, we did a control study mimicking the screening work flow (Supplementary Fig. 3 ) on three 384-well plates and demonstrating high consistency in Ct values (coefficient of variation (CV), 1-2%; average Z′ values, 0.78 (Fig. 1e) ). Differences in Ct values for WT-IKBKAP were minimal among replicate wells of the same plate. However, more marked differences were observed between wells of independent plates, prompting us to perform the final screen in triplicate.
We screened a library of 6,912 small molecules (20,736 treatment conditions in total). The library contained a broad set of biologically active and structurally diverse compounds from multiple commercial sources covering drugs approved by the US Food and Drug Administration, known bioactives and experimental substances 13 . Compounds were screened at 10 µM in 1% DMSO, with each plate containing 1% DMSO control wells. Z′ values for the control plates in all three sets of the screen indicated excellent reproducibility ( Supplementary Fig. 4 ). Using fold-difference analysis of WT-IKBKAP to S18 ratios and a binning method taking into account robustness of replicate data, we nominated 28 compounds as potential rescuers of the WT-IKBKAP levels (0.4% hit rate). In addition, we used an alternative rank-based selection algorithm that nominated an additional 15 candidate 'hits' (Fig. 2a) . For the rank-based method, we calculated the average WT-IKBKAP rank across the three replicate wells (ranks from 1-352), after elimination of compounds with low S18 values and correction for respective MU-IKBKAP ranks (Online Methods). This method was used as a complementary strategy to the fold-difference method to reduce the impact of variability in genes expressed at low levels and to find potential compounds that selectively induce WT-IKBKAP (that is, increase the ratio of WT-IKBKAP/MU-IKBKAP). (The list of the 43 nominated compounds including structure information is provided in Supplementary Table 2 .) Out of 43 hits, only 35 were commercially available for further studies. After additional validations including dose-response and cytotoxicity assays (with 12 different concentration points), use of an alternative housekeeping gene (GAPDH) and finally revalidation of WT-IKBKAP expression under standard 6-well culture conditions ( Fig. 2a,b) , we pursued eight hits for further studies: glucosaminic acid (GA); SKF-86466 Hydrochloride (SKF); phenindione (PD); dihydrojasmonic acid (DHJ); cyclosporine (CSP); cyproterone (CPT); atropine (AT); 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl) amino)-3-(((5-(carboxymethyl)-4-methyl-2-thiazolyl)thio)methyl)-8-oxo-, disodium salt, (6R,7R) (THIA). Notably, the eight compounds that significantly (P < 0.05-0.0001) increased WT-IKBKAP expression in FD-NC precursors showed differential potency for IKBKAP induction in other cell types, such as undifferentiated FD-iPSCs, FD-fibroblasts and FD-lymphoblasts ( Supplementary Fig. 5a-c) .
The tissue-specific bias in regulating WT-IKBKAP expression supports the argument for doing primary screens in symptom-relevant cells such as FD-NCs. Surprisingly, compounds did not trigger significant increases in WT-IKBKAP in control NCs (derived from H9 hESCs; Supplementary Fig. 5d ), suggesting a possible feedback mechanism preventing supraphysiological WT-IKBKAP levels in control cells.
We next tested whether regulation of WT-IKBKAP expression by the eight compounds is reproduced in FD-NCs from additional iPSC clones either from the same (clone 4) or a different (clone 101) patient ( Fig. 2c) . All compounds, with the exception of THIA, had similar potency across the various FD-NC precursor lines, suggesting that the effects are generally not dependent on either clone or patient. THIA increased WT-IKBKAP in most clones when FD-iPSC NCs from additional patients were tested (Supplementary Fig. 5e ).
WT-IKBKAP but not MU-IKBKAP is translated into IKAP protein. We observed that several of the eight compounds increased IKAP protein expression as measured by semi-quantitative western blot analysis ( Fig. 2d) . Induction of IKAP protein levels was similar to that observed after treatment with kinetin (K), the compound previously shown to partially rescue disease phenotypes in our FD-iPSC model 2 , and similar to the levels in NC precursors derived from hESCs or control iPSC lines (H9, C14; Fig. 2d ). There was a significant (P = 0.0343) correlation between WT-IKBKAP transcript and IKAP protein levels, whereas no such correlation was seen between protein expression and MU IKBKAP ( Supplementary  Fig. 5f-h npg l e t t e r s proliferation or cell death, parameters that could indirectly affect IKBKAP levels ( Supplementary Fig. 6 ).
Although short-term (48 h) compound treatment was sufficient to induce a robust increase in expression of WT-IKBKAP ( Fig. 2b) , it did not affect expression of autonomic markers such as ASCL1 (Mash1) and SCG10 ( Supplementary Fig. 7a,b) . Therefore, we next tested the potency of each compound in long-term assays by treating cells for 28 d (from FD-iPSC through FD-NC stage). None of the compounds affected the percentage of HNK1 + FD-NC-precursors at day 28 ( Supplementary Fig. 7c ), suggesting that treatment did not interfere with cell differentiation. The levels of WT-IKBKAP in purified FD-NCs increased for most compounds after long-term treatment compared with the DMSO group ( Supplementary Fig. 7d ). Notably, we observed significant increases in ASCL1 (Mash1) and SCG10 (P < 0.05) expression, particularly after treatment with SKF ( Fig. 2e,f) . Indeed, with SKF, ASCL1 (Mash1) and SCG10 expression was similar to that found in NCs from wild-type lines. Despite a nearly complete rescue of autonomic marker expression, none of the eight compounds rescued the reduced migratory propensity of FD-NC precursors (Fig. 2g) , a result that mimicked our previous findings with kinetin 2 . It also remains to be determined whether long-term SKF treatment is required to capture the developmental stage most sensitive for rescuing autonomic neurogenesis or whether long-term treatment starting at late time points can be equally effective.
In a first attempt to address potential mechanisms by which compounds can increase IKBKAP expression, we focused on SKF (doseresponse in Supplementary Fig. 7e ). SKF is a known α 2 -adrenergic receptor (α 2 AR) antagonist without known inverse agonist activity 14 . SKF showed particularly promising results in rescuing expression of autonomic markers, raising the question of whether α2AR activity could be involved in regulating IKBKAP expression. The family of α2ARs acts as G protein-coupled receptors (GPCRs) in association with the G i heterotrimeric G protein. There are three different subtypes of α2ARs: α 2A , α 2B , α 2C . The alpha subunit of the inhibitory G protein (dissociated Gi) associates with adenylcyclase and inhibits its activity, resulting in decreased intracellular cAMP levels. We first confirmed expression for each of the three subunits (α 2 A, α 2 B and α 2 C) of α 2 AR in undifferentiated FD-iPSCs, differentiated FD-iPSCs (day 12 of neural induction) and purified and/or expanded FD-NCs by RT-PCR 15 (Fig. 3a, Supplementary Fig. 8a,b and Supplementary  Table 1 ). Next we tested functional analogs of SKF that are either generic α 2 AR antagonists (yohimbine, YOH) or specific to each subunit of α 2 AR (BRL-44408 (BRL) for subunit A, imiloxan (IMI) for B, spiroxatrine (Spi) and JP-1302 (JP) for C, and RX821002 (RX) for D). YOH, BRL, IMI, Spi and JP (at 1 µM) significantly (P < 0.05-0.0001) increased IKBKAP level immediately after exposure ( Fig. 3b,c ; 30-min exposure), whereas no such effects were observed upon treatment with RX. RX exhibits selectivity for α2D-adrenoceptors 16 , a receptor subtype expressed in murine but not in human tissues. IKAP protein levels were also increased compared with control ( Fig. 3d ) 48 h after treatment with YOH or SKF. Despite the large spike of IKBKAP mRNA induction 30 min after YOH treatment, the levels of mRNA and protein induction at 48 h were similar between YOH and SKF.
Functional analogs of SKF, such as YOH, were included in our HTS collection but were not identified as hits in our initial analysis. This is probably because the compound concentrations for the primary screen (10 µM) were suboptimal for YOH (Fig. 3b) , and because a different time period was selected between compound exposure and IKBKAP measurement (30 min versus 48 h). Exposure of FD-iPSC-derived NCs to agonists of α 2 AR (xylazine or p-iodoclonidine hydrochloride) resulted in time-dependent decreases in IKBKAP levels (Fig. 3e) . However, the combination treatment of xylazine and SKF or YOH did not significantly decrease IKBKAP levels ( Fig. 3f ), suggesting complex interactions of agonists and antagonists at α 2 AR. To further address the specificity of α 2 AR modulation on IKBKAP expression, we tested the impact of SKF and xylazine after a sequential, l e t t e r s time-dependent treatment paradigm. FD-NCs were exposed to DMSO, xylazine or SKF (20 µM, 10 µM or 2 µM) for 5 min and then switched to a medium containing DMSO, xylazine or SKF (20 µM, 10 µM or 2 µM) for an additional 30 min in various permutations (Fig. 3g) . The effects of SKF pre-treatment on FD-NC were abolished by xylazine. Conversely, the effects of xylazine pretreatment on FD-NC were overcome by SKF treatment in a dose-dependent manner, further arguing that SKF acts primarily through modulating A2AR. Regulation of CREB phosphorylation is a well-known downstream mediator of α 2 AR signaling-mediated, cAMP-induced regulation of pKA. Accordingly, treatment with either of the α2-adrenoceptor antagonists SKF or YOH led to an increase in intracellular cAMP levels that could be blocked by exposure to xylazine (Fig. 3h,i) . Treatment with cell-permeable dibutyryl-cAMP (cAMP) or forskolin (FK) was able to mimic the SKF effect (Fig. 3j) . Furthermore, exposure to SKF, IMI and YOH increased the levels of phosphorylated CREB (p-CREB) in FD-NCs, whereas exposure to H89 or KT5720 (selective protein kinase A inhibitors) blocked the effect of both SKF and YOH on IKBKAP expression ( Fig. 3k,l) . These data confirm that pKA activity is required to mediate SKF and YOH function. IKBKAP promoter analysis using the transcription element search system (TESS, http://www.cbil.upenn.edu/cgi-bin/tess/tess) shows the presence of conserved CREB-binding domains 17 . We developed a luciferase assay based on the corresponding human IKBKAP promoter region, which demonstrated strong promoter activation following SKF treatment that was repressed by xylazine or H89 (Fig. 3m) . Our pharmacological studies strongly suggest that SKF induces IKBKAP expression, at least in part, through classical α 2 AR signaling and cAMP-mediated activation of pKA and pCREB. The regulation of cAMP levels and its impact on IKBKAP expression levels appear to follow a complex temporal pattern and probably intersect with other signaling pathways. Notably, CSP, GA and AT also showed evidence of increased cAMP or p-CREB levels, suggesting that this pathway could contribute to the action of other molecules from our screen ( Supplementary  Fig. 8c,d) . Kinetin, a compound known to act on IKBKAP splicing, did not activate cAMP in FD-iPSC NC precursors, supporting the specificity of this effect. The different mechanisms of action for SKF and kinetin point to the possibility of combining modalities for future therapeutic applications.
Currently there are no animal models of FD that faithfully recapitulate the clinical symptoms of the disease beyond measuring tissuespecific IKBKAP splicing 18, 19 . Other unresolved issues include our lack of understanding as to why SKF or other compounds, including kinetin, do not rescue the migratory defect of FD-NCs, and whether any of the compounds will ameliorate degenerative aspects of the disease, such as the survival of postmitotic sensory or autonomic neurons. An important challenge for the future will be to make rational decisions in selecting the most promising compounds to pursue for l e t t e r s clinical translation. Although there are obvious criteria, such as data on safe in vivo levels of a compound in relation to its IKBKAP activity or the ability to cross the blood-brain and blood-ganglia barriers, additional in vivo assays will be required for preclinical testing of our candidate compounds in a disease background. We speculate that an in vitro trial that systematically tests compounds in iPSCderived cells from FD-patients may contribute to a rational clinical trial design. Since the first reports on establishing human iPSCs, the use of disease-specific cells for drug validation and drug discovery has been an important goal. Our data demonstrate that it is feasible to perform primary screens in iPSC-derived cells for thousands of clinically relevant compounds. The development of similar assays for other diseases could herald an emerging drug discovery approach that moves us closer to an era of personalized medicine.
MEtHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
ONLINE MEtHODS
Culture of fibroblast, lymphoblast, hESCs and iPSCs. FD-fibroblasts (GM04958 from Coriell) were maintained with DMEM, 10% serum, 1% nonessential amino acids (AA), 1 mM l-glutamine (Glut) and 0.1 mM β-mercaptoethanol (MTG). FD-lymphoblast (GM05105B) was obtained from Coriell and maintained with RPMI 1640, 2 mM l-glutamine and 15% fetal bovine serum. Undifferentiated H9 (WA09) hESCs, control C14 (derived from human fetal lung fibroblasts (MRC-5) purchased (ATCC, CCL-171)), control 02036 iPSC line (derived from GM02036 (Coriell)), FD-iPSC line #22, #4 (derived from GM04958 (Coriell)) and #101 (derived from GM04589 (Coriell)) were cultured on mitotically inactivated mouse embryonic fibroblasts in a serum replacementcontaining culture medium supplemented with 4 ng/ml FGF2 as used routinely for hESC cultures 2 . To generate iPSC lines, we used bicistronic lentiviral vectors containing vexGFP, mCitrine, mCherry and mCerulean, linked by a P2A peptide preceded by a Gly-Ser-Gly linker to the cDNAs of human Oct4, Sox2, Klf4 and c-Myc, respectively, which were cloned in a lentiviral vector under the transcriptional control of hPGK promoter as previously reported 20 . All the iPSC lines used for differentiation experiments were between passages 20 and 40.
Differentiation of hESCs and iPSCs.
For neural induction, hESCs and iPSCs were plated at 5-20 × 10 3 cells on a confluent layer of irradiated (50 Gy) stromal cells (MS-5) in 60-mm cell culture plates in KSR medium 21 . After 10 d in serum replacement medium containing 250 nM Noggin (R&D Systems) and 10 µM SB431542 (Tocris), cultures were switched to N2 medium with 200 ng/ml SHH, 100 ng/ml FGF8 (from day 10 to day 16). Medium was changed every 2-3 d, and growth factors were added at the following concentrations as described previously (day 16 to day 20): 200 ng/ml SHH, 100 ng/ml FGF8, 20 ng/ml brain-derived neurotrophic factor (BDNF) (all R&D Systems) and 0.2 mM ascorbic acid (AA) (Sigma-Aldrich). Rosette structures were harvested mechanically around day 20 of differentiation (termed passage 0; P0) and gently replated on 15 µg/ml polyornithine/1 µg/ml laminin (PO/Lam)coated culture dishes in N2 medium (termed passage 1; P1). P1 cultures were supplemented with SHH, FGF2, AA and BDNF. After 6-7 d of P1 culture, cells were triturated into single cells after exposure to Accutase (Innovative Cell Technologies, Inc., 10 min in incubator) and labeled with antibodies for flow cytometry. FACS sorting (HNK1; Sigma-Aldrich) was done on a MoFlo (Dako). After negative gating for four-factor color (to exclude transgenereactivating cells), HNK1 (anti-mouse IgM PE-Cy7 antibody, BD) positive cells were isolated. Sorted cells were plated on culture dishes pre-coated with 15 µg/ml polyornithine/1 µg/ml laminin/10 ng/ml fibronectin (PO/Lam/Fib). hESC-NC were maintained in N2 medium supplemented with 20 ng/ml of FGF2 and 20 ng/ml of EGF changed every 2-3 d and passaged every 4-6 d, as previously described. Two weeks after cell sorting and in vitro expansion, FD-NCs as well as control NCs were frozen down and thawed for further usages. For the validation of neuronal potential, FD-NC were plated in PO/Lam/Fib plate (10,000 cells per 10 µL) and further differentiated in medium supplemented with BDNF (20 ng/ml), GDNF (20 ng/ml), NGF (20 ng/ml) and dbcAMP (0.5 mM) for 10 d. Neuronal cells derived from FD-NC were fixed in 4% paraformaldehyde and stained with the primary antibodies for peripherin (Sigma-Aldrich) and Brn3a (Millipore). Appropriate secondary antibodies (Molecular Probes) and DAPI counter-staining was used for visualization. For cell cycle analysis, treated FD-NCs were dissociated with trypsin and subjected to cycle analysis by FACS after propidium iodidecitrate solution treatment (50 mg/ml propidium iodide, 0.1% sodium citrate dihydrate, 200 mg/ml RNaseA and 0.1% Triton X-100). In brief, FD-NCs (0.5 million) were washed once with PBS, incubated with propidium iodidecitrate solution for 10 min in the dark, and analyzed. Analysis was performed with the FlowJo software (version 8.8.4; TreeStar).
Miniaturization of tissue culture and qPCR assay in 384-well format. 384-well microtiter plates (Corning, #3985) were washed once with 80 µl per well of sterile 1× PBS without CaCl 2 and MgCl 2 (Invitrogen). PBS was added using an automated Multidrop384 dispenser (Thermo Scientific, Waltham, MA) and aspirated using an automated plate washer ELx405 (Biotek Instruments, Winooski, VT) at room temperature. All additions and aspirations were done as described unless otherwise noted. After wash, 80 µL per well of 15 µg/mL of polyornithine in 1× sterile PBS was added and plates were incubated at 37 °C and 5% CO 2 for 48 h. Polyornithine-treated plates were then washed three times with 80 µl per well of 1× sterile PBS. Afterward, 80 µL per well of a 2 µg/ml laminin and 2 µg/ml fibronectin mixture in 1× sterile PBS was added and plates were incubated at 37 °C and 5% CO 2 for 48 h. The coating mixture was aspirated at least 6 h before seeding FD-NCs.
To optimize cell seeding densities, we seeded FD-NCs in 384-well microtiter plates at final cell densities of 1,250, 2,500, 5,000, 7,500 or 10,000 cells per well in 45 µL of complete media using an automated Multidrop384 dispenser (Thermo Scientific, Waltham, MA). The plates were incubated at 37 °C and 5% CO 2 in a Steri-cult incubator (Thermo Scientific). After 24, 48 or 72 h incubation, 5 µL of Alamar Blue was added using Flexdrop (PerkinElmer). The cells were then incubated for another 24 h, and the fluorescence intensity was read on the Amersham LEADseeker Multimodality Imaging System equipped with Cy3 excitation and emission filters and FLINT epi-mirror. A cell density of 7,500 cells per well was selected as the optimal cell seeding density for the assay.
Pilot screen for rescuers of WT-IKBKAP. FD-NCs were seeded in coated 384-well microtiter plates (Corning, #3985) at 7,500 cells per well in 45 µL of complete media using an automated Multidrop384 dispenser (Thermo Scientific, Waltham, MA) and incubated at 37 °C and 5% CO 2 in Steri-cult incubator. After 24 h of incubation, 5 µL per well of compounds were added (100 µM; final concentration in assay is 10 µM in 1% DMSO) and 1% DMSO (column 13 and 14) to assay plates containing cells using PP-384-MM Personal Pipettor with a custom 384 head (Apricot Designs, Monrovia, CA) and incubated at 37 °C and 5% CO 2 for an additional 48 h in Steri-cult incubator. In order to determine cell viability and growth before mRNA isolation, an additional 384-well microtiter plate was aspirated and stained with 5 µM of CalceinAM (Invitrogen, C3099) and imaged using the INCA2000 (GE Healthcare, Piscataway, NJ). After verification of cell viability and growth, mRNA was isolated using mRNA TurboCapture 384 Kit (Qiagen, #72271) adapting the protocol recommended by the manufacturer. After isolation, 5 µl per well of mRNA was transferred to 384-well PCR reaction plates (Applied Biosystems, #4343814) using PP-384-MM Personal Pipettor with a custom 384 head (Apricot Designs, Monrovia, CA). Afterward, 5 µL per well of RT-PCR master mix was added as described for mRNA isolation. The plates were sealed with MicroAmp Optical Adhesive Film (Applied Biosystems, #4311971) and spun briefly at 2,000 r.p.m. The formulation of the RT-PCR master mix ( Supplementary Table 1 ) and addition was completed under sterile conditions in a laminar flow hood. Amplification of cDNA and qPCR was performed in the same well using 7900HT (Applied Biosystems) on automation mode ( Supplementary Table 1 ). No positional effects were observed using automation during qPCR. The assay was run in triplicate and a plate-byplate analysis was conducted to determine average cycle threshold (Ct) of 18S, WT and MU transcripts, standard deviation (STDEV), coefficient variant (CV) and Z′ values. Fold-difference values were calculated using the comparative Ct method (∆∆ Ct method). The statistical performance of the assay was assessed by measuring the control values of each plate individually.
Chemical libraries. The library used for the screen combines 6,912 chemicals obtained from MicroSource, Prestwick, LOPAC and other commercial sources. The MicroSource Library contains 2,000 biologically active and structurally diverse compounds from known drugs, experimental bioactives and pure natural products. The library includes a reference collection of 160 synthetic and natural toxic substances (previously characterized as being inhibitors of DNA/RNA synthesis, protein synthesis, cellular respiration and membrane integrity), a collection of 80 compounds representing classical and experimental pesticides, herbicides and endocrine disruptors, and a singular collection of 720 natural products and their derivatives. The latter collection includes simple and complex oxygen heterocycles, alkaloids, sequiterpenes, diterpenes, pentercyclic triterpenes, sterols and many other diverse representatives. The Prestwick Chemical Library is a unique collection of 1,119 high purity chemical compounds, all off patent and selected for structural diversity and broad spectrum, with established activities in therapeutic areas including neuropsychiatry, cardiology, immunology, anti-inflammatory and analgesia, with known safety, and bioavailability in humans. Approximately 90% of the library consists of marketed drugs and 10% of bioactive alkaloids or related npg substances. Similarly, the LOPAC library available from Sigma-Aldrich comprises 1,280 pharmacologically active compounds involved in a broad range of cell signaling and neuroscience areas. We also used additional small compound libraries such as Sequoia (90), Signalosome (58) as well as other internal collections (845) available at MSKCC HTS core facility. The agonist, antagonist for α 2 AR, Forskolin and H89 were purchased from Tocris Bioscience. cAMP was purchased from Sigma-Aldrich.
Hit selection. We used two independent strategies to nominate candidate hits out of the 6,912 compounds tested in triplicate. The first strategy was based on fold-difference analysis of WT-IKBKAP to S18 comparing compound to DMSO control-treated wells. Hits were defined as a more than twofold increase in at least two out of the three replicates. Twenty-eight compounds fulfilled those criteria. The second strategy was based on ranking compounds according to WT-IKBKAP expression levels. Wells in each 384-well plate were ranked from 1 (highest WT-IKBKAP levels) to 352 (lowest WT-IKBKAP levels) with 32 wells serving as DMSO controls. Wells with Ct levels for S18 of >14 were excluded from ranking and marked as possible compounds exhibiting toxicity. The 50 compounds with the lowest average rank number (from the three replicate screens) out of all 6,912 compounds were analyzed further. Among those candidate hits a complementary score was established for MU-IKBKAP expression ranging from 1 (lowest MU-IKBKAP levels) to 352 (highest IKBKAP levels). Combining both rankings for WT-and MU-IKBKAP was used for the identification of the 15 compounds from this second hit selection strategy. Table 1 ). For detection of subunits of α 2 adrenergic receptor, PCR amplification was carried out in a final volume of 25 ml containing 2 µl of cDNA obtained from the RT reaction, 12.5 ml ReddyMix PCR master mix. Denaturation at 94 °C for 2 min; and amplification for 40 cycles of 94 °C for 15 s, annealing at 55 °C for 20 s, and extension at 72 °C for 45 s. A final extension of 72 °C for 10 min was run after the 40 cycles. PCR products were analyzed by electrophoresis on 2% agarose gel 15 . Migration/motility assay was performed following published protocol 22 . In brief, cells were treated with mitomycin C (2 ng/ml for neural crest cells) for 2 h and dissociated with Accutase. A total of 20,000 cells were plated in each well of a PO/Lam/ Fib-coated 96 well plate. At 24 h after plating, each well was scratched using a 100-µl pipette tip and washed, and the image was taken (0 h) as a reference point for subsequent quantification. At 48 h after scratching, cells were fixed by 4% paraformaldehyde, permeabilized with 0.05% Triton-X solution and stained with DAPI for quantification of DAPI+ nuclei (48 h) in the identical fields marked at day 0. To measure level of cAMP, cAMP complete ELISA kit according to manufacturer's instruction (Enzo Life Science). For Ki67, Caspase-3 and phosphorylated-CREB /DAPI ratio quantification, cells were subjected to Ki67 (1:100, Dako), Caspase-3 (1:1000, BD) and phosphorylated-CREB (1:500, Cell Signal) immunocytochemistry, and four 0.15 mm 2 microscopic fields were imaged and analyzed using ImageJ software (NIH, Bethesda, MD).
In brief, Ki67 or Caspase-3 and DAPI channels were subjected to thresholding independently, the stain surface area was measured, and finally the ratio of the surface areas was calculated. For testing functional SKF analogs (α 2 AR antagonist) and α 2 AR agonist, each compound or mixed combination along with DMSO (final 1%, v/v) was treated for 30 min in FD-NCs (plated in 10,000 cells per cm 2 , 24 h before treatment) and collected for further RNA extraction. For immunoblot, cells were lysed with histone lysis buffer from Aton protocol (10 mM MgCl2, 10 mM Tris-HCl, 25 mM KCl, 1% Triton X-100, 8.6% sucrose, tablet of protease inhibitor). Protein concentration was measured by the Bradford Assay (Bio-Rad). For immunoblot, whole cell extract (4,000,000 cells per sample) were boiled for 5 min in Laemmle sample buffer before separation by electrophoresis on 4-12% Bis-Tris gel in MOPS SDS running buffer at 100V for 2 h using a iBlot electroblotter (Invitrogen). Protein was transferred to nitrocellulose membrane using the iBlot gel transfer device (Invitrogen). Nonspecific protein binding was prevented by blocking the membrane with 10% skim milk in PBS (0.1% Tween-20). Membrane was incubated at 4 degrees overnight in 10% skim milk with primary antibodies (IKAP (1:200), GAPDH (1:10,000)). After five washes with PBS (0.1% Tween-20), the blot was incubated with respective secondary antibodies (mouse (1:5,000), rabbit (1:20,000) at room temperature. ECL kit, Western Lightning Plus-ECL, was used for detection according to manufacturer's instruction (PerkinElmer). Polyclonal antibody IKAP was purchased from Santa Cruz and monoclonal antibody GAPDH was purchased from Thermo Scientific. Secondary antibodies were all purchased from Jackson ImmunoResearch. ECL kit, Western Lightning Plus-ECL, was used for detection according to manufacturer's instruction (PerkinElmer). For the Luciferase assay with FD-NC carrying IKBKAP promoter construct, the 627 bp DNA sequence at the human IKBKAP gene 5′ end (containing cAMP-responsive element) was amplified by PCR method (primer sequences are available in Supplementary Table 1) , and purified PCR product was digested with XhoI and HindIII restrictive enzymes for cloning into pGL3-Enhancer vector (Promega). Selected clones were confirmed to be double digested and the final clone was sequenced. FD-NC were transfected with AMAXA nucleofection kit (B-16 protocol, 5 µg of plasmid per 5 million cells) and cultured for 26 h. Transfected FD-NCs were treated by different small molecules for 20 min and harvested with Steady-Glo Luciferase Kit (Promega). Luminescence intensity was measure by TopCount luminometer (PerkinElmer). Each value was normalized with those of empty wells and further relative values were acquired by dividing with those of nontransfected FD-NC cells.
Statistical analysis. The Z′ factor was used to assess assay performance 23 . The Z′ factor constitutes a dimensionless parameter that ranges from 1 (infinite separation) to <0. It is defined as: Z′ = 1 − (3σ c+ + 3σ c− ) / |µ c+ − µ c− | where σ c+ , σ c− , µ c+ and µ c− are the standard deviations (σ) and averages (µ) of the high control (WT or MU transcript; FD-NCs treated with 1% DMSO (v/v)) ( c+ ) and the low control (18S transcript; FD-NCs treated with 1% DMSO (v/v)) ( c− ). Z′ factor between 0.5 and 1 indicates an excellent assay with good separation between controls. Z′ factor between 0 and 0.5 indicates a marginal assay and <0 signifies a poor assay with no separation between controls.
The data were processed using Prism 5.0 software. Values are reported as means ± s. d. Comparisons among values for all groups were performed by one-way ANOVA. Dunnett's and Newman-Keuls Multiple Comparison Test were used to determine the level of significance as indicated in text.
